Benzinga · Aug 6, 2026
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
KY
NASDAQ · KYMR
Kymera Therapeutics, Inc.
Healthcare · Biotechnology
$120.23
Down-$5.32 (-4.24%)
Updated Aug 28, 2026, 7:52 AM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.32B
- P/E ratio
- -25.98
- Dividend yield
- 0.00%
- 52-week range
- $69.48 – $130.05
- Volume
- 595.7K
- Avg. volume
- 951.53K
Price performance
KYMR price history
1M range · 21 trading sessions · Daily adjusted prices
KYMR closed at $120.23 after 21 trading sessions, up 12.35% for the selected period.
- Last close
- $120.23
- Period change
- +12.35%
- Period low
- $100.31
- Period high
- $127.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $124.99 | $125.065 | $119.98 | $120.23 | 595.7K |
| Aug 26, 2026 | $126.24 | $126.315 | $123.39 | $125.55 | 558.34K |
| Aug 25, 2026 | $122.64 | $127.85 | $121.60 | $126.64 | 925.75K |
| Aug 24, 2026 | $119.98 | $121.56 | $116.46 | $121.05 | 466.86K |
| Aug 21, 2026 | $122.87 | $125.71 | $119.77 | $119.80 | 503.43K |
| Aug 20, 2026 | $124.95 | $125.45 | $121.13 | $121.50 | 580.75K |
| Aug 19, 2026 | $124.63 | $127.36 | $121.825 | $127.31 | 842.93K |
| Aug 18, 2026 | $119.75 | $122.14 | $118.09 | $121.38 | 640.89K |
| Aug 17, 2026 | $117.39 | $122.59 | $117.04 | $121.41 | 704.71K |
| Aug 14, 2026 | $112.90 | $118.04 | $110.05 | $117.39 | 468.58K |
| Aug 13, 2026 | $114.73 | $114.73 | $112.44 | $114.42 | 481.72K |
| Aug 12, 2026 | $110.22 | $115.00 | $109.085 | $114.03 | 961.01K |
| Aug 11, 2026 | $108.79 | $110.37 | $106.30 | $109.62 | 2.38M |
| Aug 10, 2026 | $106.63 | $109.05 | $106.035 | $108.58 | 404.89K |
| Aug 7, 2026 | $106.61 | $108.12 | $104.78 | $107.52 | 463.57K |
| Aug 6, 2026 | $105.00 | $107.04 | $103.37 | $106.41 | 510.92K |
| Aug 5, 2026 | $104.86 | $107.90 | $103.835 | $105.48 | 586.32K |
| Aug 4, 2026 | $101.75 | $104.95 | $100.53 | $104.39 | 601.56K |
| Aug 3, 2026 | $102.77 | $103.00 | $99.52 | $100.31 | 666.8K |
| Jul 31, 2026 | $106.25 | $106.725 | $102.13 | $103.40 | 511.84K |
| Jul 30, 2026 | $105.66 | $107.815 | $104.315 | $107.01 | 444.45K |
Latest KYMR news
The latest Smart Investors Daily articles mentioning KYMR.
Stock researchCompany · Overview
KYMR research
Overview
Company profile and research snapshot.
Company profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $114.31
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Wells Fargo | Overweight | — |
| Aug 6, 2026 | Barclays | Overweight | — |
| Jul 30, 2026 | Deutsche Bank | Hold | — |
| Jul 28, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 5, 2026
Kymera Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Kymera Therapeutics, Inc.
SeekingAlpha · Aug 5, 2026
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsJustine Koenigsberg - Vice President of Investor...
Benzinga · Aug 5, 2026
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
